New hope for chronic itch: dupilumab tackles prurigo nodularis

NCT ID NCT04202679

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug dupilumab in 160 adults with prurigo nodularis, a skin condition causing intense itching and bumps. Participants received either dupilumab injections or a placebo for up to 24 weeks. The main goal was to see if dupilumab could reduce itch by at least 4 points on a 0-10 scale by week 12.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (an injectable drug that blocks inflammation)
What this could lead to: If it works, this could provide a new treatment option for people with prurigo nodularis who have severe itching and skin bumps that don't improve with creams.
What could go wrong: This is a completed Phase 3 trial, but results are not yet widely available. The drug may not work for everyone, and side effects like injection reactions or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurodermatitis prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEURODERMATITIS

Contacts and locations

Locations

Investigational Site Number :1240001

Toronto, Ontario, M5A 3R6, Canada
Investigational Site Number :1240002

Calgary, Alberta, T2G 1B1, Canada
Investigational Site Number :1240006

Surrey, British Columbia, V3R 6A7, Canada
Investigational Site Number :1240007

Markham, Ontario, L3P 1X3, Canada
Investigational Site Number :1240008

Newmarket, Ontario, L3Y 5G8, Canada
Investigational Site Number :1240009

Saskatoon, Saskatchewan, S7K 0H6, Canada
Investigational Site Number :1520001

Santiago, Reg Metropolitana de Santiago, 7640881, Chile
Investigational Site Number :1520002

Santiago, Chile
Investigational Site Number :1520003

Santiago, Reg Metropolitana de Santiago, 7580206, Chile
Investigational Site Number :1520004

Santiago, Reg Metropolitana de Santiago, 80004005, Chile
Investigational Site Number :1520005

Valdivia, Los Ríos Region, 5110683, Chile
Investigational Site Number :1520006

Osorno, Reg Metropolitana de Santiago, 5311523, Chile
Investigational Site Number :1580001

Taipei, 10002, Taiwan
Investigational Site Number :1580002

Taipei, 10449, Taiwan
Investigational Site Number :1580005

Hsinchu, 30059, Taiwan
Investigational Site Number :1580006

Kaohsiung City, 833, Taiwan
Investigational Site Number :1580008

Taichung, Taiwan
Investigational Site Number :2500001

Brest, 29200, France
Investigational Site Number :2500002

Lille, 59037, France
Investigational Site Number :2500003

Toulouse, 31059, France
Investigational Site Number :2500004

Paris, 75010, France
Investigational Site Number :2500005

Reims, 51100, France
Investigational Site Number :2500006

Lyon, 69003, France
Investigational Site Number :2500007

Bordeaux, 33075, France
Investigational Site Number :2500008

Le Mans, 72037, France
Investigational Site Number :3480002

Orosháza, 5900, Hungary
Investigational Site Number :3480003

Szeged, 6720, Hungary
Investigational Site Number :3480004

Debrecen, 4032, Hungary
Investigational Site Number :3480005

Pécs, 7632, Hungary
Investigational Site Number :3800001

Rozzano, Milano, 20089, Italy
Investigational Site Number :3800002

Milan, 20122, Italy
Investigational Site Number :3800003

Catanzaro, 88100, Italy
Investigational Site Number :3800004

Ancona, 60032, Italy
Investigational Site Number :4100001

Seoul, Seoul-teukbyeolsi, 06973, South Korea
Investigational Site Number :4100002

Busan, Busan, 49241, South Korea
Investigational Site Number :4100003

Bucheon-si, Gyeonggi-do, 14584, South Korea
Investigational Site Number :4100005

Seoul, Seoul-teukbyeolsi, 03722, South Korea
Investigational Site Number :4100006

Seoul, Seoul-teukbyeolsi, 07441, South Korea
Investigational Site Number :4100007

Incheon, Incheon-gwangyeoksi, 21431, South Korea
Investigational Site Number :6200001

Coimbra, 3000-075, Portugal
Investigational Site Number :6200002

Lisbon, 1998-018, Portugal
Investigational Site Number :6200003

Porto, 4099-001, Portugal
Investigational Site Number :7240001

Pontevedra, Galicia [Galicia], 36071, Spain
Investigational Site Number :7240002

Zaragoza, 50009, Spain
Investigational Site Number :7240003

Valencia, 46026, Spain
Investigational Site Number :7240004

Córdoba, 14004, Spain
Investigational Site Number :7240007

Madrid, 28034, Spain
Investigational Site Number :7240008

Santullano, Principality of Asturias, 33619, Spain
Investigational Site Number :7240009

Badalona, Barcelona [Barcelona], 08916, Spain
Investigational Site Number :8260001

Redhill, Surrey, RH1 5RH, United Kingdom
Investigational Site Number :8400001

Sugar Land, Texas, 77479, United States
Investigational Site Number :8400002

Plainfield, Indiana, 46168, United States
Investigational Site Number :8400003

Baltimore, Maryland, 21205, United States
Investigational Site Number :8400005

Pembroke Pines, Florida, 33028, United States
Investigational Site Number :8400006

East Windsor, New Jersey, 08520, United States
Investigational Site Number :8400008

Sacramento, California, 95816, United States
Investigational Site Number :8400054

Fort Smith, Arkansas, 72916, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.